1 Sequencing from leftover material of stored rapid Ag Tests (Ag-RDTs): a

2 gamechanger in genomic surveillance?

- 3
- 4 Annabel Rector¹, Mandy Bloemen¹, Gilberte Schiettekatte³, Piet Maes¹, Marc Van Ranst^{1,2}
- 5 and Elke Wollants^{1*}
- 6
- 7 ¹KU Leuven, Rega Institute, Department of Microbiology, Immunology and Transplantation,
- 8 Laboratory of Clinical and Epidemiological Virology, 3000 Leuven, Belgium.
- 9 ²University Hospitals Leuven, Department of Laboratory Medicine, National Reference Center for
- 10 Respiratory Pathogens, 3000 Leuven, Belgium.
- ³ Center for Medical Analysis, Departement of Molecular Biology and Immunology, 2200 Herentals,
 Belgium
- 13
- 14
- 15
- *Corresponding author: <u>elke.wollants@kuleuven.be</u> ; +32 16 32 13 41; Herestraat 49 box 1040,
- 17 BE3000 Leuven, Belgium
- 18
- 19 ORCID: Annabel Rector (0000-0003-3714-449X); Mandy Bloemen (0000-0002-3395-0462); Piet Maes
- 20 (0000-0002-4571-5232); Marc Van Ranst (0000-0002-1674-4157); Elke Wollants (0000-0002-4057-

21 2236).

22

24 ABSTRACT

25	Archived lateral flow antigen-detection rapid diagnostic tests (Ag-RDTs), used in the diagnosis of
26	COVID-19, were successfully used to extract viral nucleic acids for subsequent RT-qPCR and
27	sequencing by Sanger or Nanopore whole genome sequencing (WGS). The method was successfully
28	applied with different brands of SARS-CoV-2 Ag-RDTs, but also with Ag-RDTs for detection of
29	influenza, rotavirus and adenovirus 40/41. The buffer used in the Ag-RDT had an important influence
30	on the RNA yield from the test stripand the efficiency of subsequent sequencing. Our finding that the
31	test strip in rapid Ag tests is suited to preserve viral genomic material, even for months at room
32	temperature, and therefore can serve as source material for genetic characterization, could improve
33	global coverage of genomic surveillance for SARS-CoV-2 as well as for other viruses.

34

35 KEY WORDS

Rapid antigen test (Ag RDT), SARS-CoV-2, influenzavirus, adenovirus, rotavirus, Sanger sequencings,
whole genome sequencing, genomic surveillance.

38

39 **INTRODUCTION**

With over half a billion cases and more than 6 million reported COVID-19 deaths since it's emergence in December 2019 [1], the COVID-19 pandemic caused by SARS-CoV-2 has brought on major challenges to health care systems and authorities worldwide. The availability of effective and safe vaccines is without question an important element in our way out of this crisis. Nevertheless, the current COVID-19 vaccines are not sufficient to prevent spread and circulation of the virus, even in highly vaccinated populations [2], and are regretfully not accessible for the entire global population [3]. Therefore, epidemiological surveillance through timely and adequate diagnostic testing for SARS-

47 CoV-2 to guide preventive measures for the control of COVID-19 will remain vital in the battle against
48 the virus.

49 Currently, two types of tests are being used in the diagnosis of SARS-CoV-2 infection. Molecular 50 assays based on the detection of viral RNA through a nucleic acid amplification test (NAAT), such as 51 real-time reverse transcription quantitative PCR (RT-qPCR), are highly sensitive and specific, but in 52 most cases require expensive laboratory facilities and trained technicians, making them less suited 53 for fast scaling-up. An alternative is the detection of viral antigens through immunodiagnostic 54 techniques such as lateral flow antigen-detection rapid diagnostic tests (Ag-RDTs) that can be visually read or processed and read by an instrument. These Ag-RDTs can be performed outside the 55 56 laboratory, provide a faster result (15 min) and can be produced much faster, cheaper and in large 57 quantities, allowing for swift upscaling of testing capacity. They can be highly specific, but are 58 generally not as sensitive as molecular tests, making them effective for identifying infected persons 59 displaying high virus shedding, who are hence most infectious [4], [5].

Although laboratory-based NAAT is still considered to be the reference standard for SARS-CoV-2 diagnosis, the WHO recommends the use of Ag-RDTs as a decentralizable, faster and reliable option, provided that the tests meet the WHO standards for Ag-RDTs (\geq 80% sensitivity and \geq 97% specificity among symptomatic individuals) [6], [7].

The continuous evolution of SARS-CoV-2 has already resulted in the emergence of several variants of interest (VOI) and of concern (VOC) which can be associated with increased transmissibility and/or immune escape [8], [9]. Therefore, genomic surveillance to allow early identification, detection, monitoring and reporting of emerging variants can be considered to be equally important as epidemiological surveillance in achieving effective mitigation and containment of the virus. Moreover, virus whole genome sequences can be used to investigate spatiotemporal spread and transmission routes, and can help in the design of diagnostic assays, antivirals and vaccines [10]–[12].

Genomic surveillance of SARS-CoV-2 can be achieved by complete genome sequencing (the golden standard) or by detection of spike protein mutations that are indicative for specific variants through sequencing of a limited region of interest within the receptor binding domain (RBD) of the viral genome [13], [14]. These techniques require the retrieval of viral genetic material from a patient sample, classically the leftover of a nasopharyngeal sample used for NAAT.

Based on our previous experience with the preservation and transport of viral material on paper strips [15]–[18], we wanted to test whether the leftover viral material in the cellulose carrier in the test strips used in SARS-CoV-2 Ag-RDTs is sufficient to allow extraction of intact viral nucleic acids and subsequent RT-qPCR, Sanger sequencing and/or whole genome sequencing (WGS).

80 Several other viruses are also frequently diagnosed with Ag-RDTs, and also in these cases obtaining 81 supplementary information regarding the type or variant through sequencing can be of importance. 82 Genomic surveillance of influenza viruses is being performed by labs worldwide within the 83 framework of the WHO's Global Influenza Surveillance and Response System (GISRS). They provide 84 essential information regarding efficacy of vaccines and antiviral drugs against currently circulating 85 influenza viruses, vaccine strain selection and the potential spill-over of animal influenza viruses to 86 humans. The surveillance of circulating genotypes of rotavirus is of crucial importance for detection 87 of novel emerging genotypes and/or antigenic drift of strains that can occur through vaccination and 88 can lead to decreased efficacy or failure of vaccines. For the cases of hepatitis of unknown etiology 89 among young children that were under investigation by ECDC at the time of writing [19], an 90 association with a (novel variant of) human adenovirus 41 (Adv41) is being considered [20], [21]. 91 Typing of positive adenovirus samples can therefore be of clinical and epidemiological relevance.

92 In this study, we evaluate the possibility to retrieve leftover material of several viruses from a range
93 of Ag-RDTs, and after longterm storage at room temperature, for use in molecular genetic analysis.

95 MATERIALS AND METHODS

96 Samples

97 For an optimal result, Ag tests need to be performed with fresh samples containing live virus. Since it 98 was not feasible to perform all Ag tests immediately on infected patients, with sampling using the 99 swab provided by the supplier, we used anonymized stored nasopharyngeal patient samples as a 100 proxy. For use on an Ag-RDT, samples need to be stored in PBS and not in inactivated medium such 101 as zymo, inactive blue or any other virus-inactivating medium that denatures proteins, since Ag-RDTs 102 detect intact viral proteins.

103 Our laboratory functions as the Belgian national reference center (NRC) for coronaviruses, 104 adenoviruses and rotaviruses. The positive samples and positive Ag-RDTs used in this study were 105 anonymized leftover materials of diagnostic samples, tested by the NRC. The use of patients' residual 106 materials by the NRC was approved by the UZ Leuven Ethics Committee.

107 Rapid Ag tests (Ag-RDTs)

108 SARS-CoV-2 Ag-RDTs that were used in this study are: Roche SARS-CoV-2 Rapid Antigen Test Nasal, 109 Roche Diagnostics, Basel, Switzerland, Ref. 9901-NCOV-01G and 9901-NCOV-06G (Roche nasal); 110 FlowFlex SARS-CoV-2 Antigen Rapid Test (Self-Testing), Acon Laboratories Inc., San Diego, CA, USA, 111 Ref. L031-118P5 (FlowFlex); Newgene COVID-19 Antigen Detection Kit – Nasal Swab, Newgene 112 Bioengeneering, Hangzhou, China, Ref. COVID-19-NG21 (Newgene); Coris COVID-19 Ag K-SeT, Coris 113 BioConcept, Gembloux, Belgium, Ref. K-1525 (Coris COVID-19); Alltest: nasal swab test, Hangzhou 114 Alltest Biotech Co. Ltd., Hangzhou, China, Ref. INCP-502-N (Alltest); Boson Rapid SARS-CoV-2 Antigen 115 Test Card, Xiamen Boson Biotech Co., Ltd., Xiamen, China, Ref. 1N40C5-2 (Boson). SARS-CoV-2 / 116 Influenza dual Ag tests that were used are: Orient Gene Influenza & COVID-19 Ag Combo Rapid Test 117 Cassette, Zhejiang Orient Gene Biotech Co., Ltd, Zhejiang, China, Ref. GCFC-525a (Orient); AMP 118 Rapid Test CoV-2 Ag + Flu A+B, AMEDA Labordiagnostik GmbH, Graz, Austria, Ref. RT2962 (AMP); 119 Nadal COVID-19 Ag+Influenza A/B plus test, Nal von minden GmbH, Moers, Germany, Ref. 243204N-

20 (Nadal). For Adenovirus 40/41 and Rotavirus dual Ag test we used the Coris GastroVir K-SeT, Coris
BioConcept, Gembloux, Belgium, Ref. K-1516 (Coris Gastro). Tests are referred in Table 1 as indicated
in bold after every test.

123 Direct testing of patients with the Ag-RDTs was done as described in the test instruction manual. For 124 testing of different Ag-RDTs with positive samples of known viral loads, nasopharyngeal swabs in PBS 125 that had been stored at 4°C were used. Hundred μ l of the PBS solution was mixed with the buffer 126 included in the test kit. The Ag-RDT test was further performed as described in the test instructions 127 manual. To assess the effect of the Ag-RDT test buffer on nucleic acid yield, we also performed Ag-128 RDT tests without using the buffer solution, by transferring 100 µL of PBS solution directly on to the 129 sample window of de test cassette. Ag-RDTs run with PBS without patient sample were used as 130 negative controls.

131 Nucleic acid extraction from Ag-RDT test strips

Ag-RDT cassettes were opened by removing the cover, the test strip was taken out and different
parts of the test strip were excised with scissors as indicated in Fig. 1.

Punch biopsies were taken from unopened Ag-RDT cassettes at the zone of the sample window and at the zone of the positive test line, by using a 2 mm diameter sterile disposable biopsy punch (KAI medical disposable biopsy punch Ref. BP-20F). The biopsy or excised part of the Ag-RDT test strip was directly added to 275 μL lysis buffer in a 96 well lysis plate for extraction with the MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit (ThermoFisher Scientific), according to the protocol for KingFisher Flex.

140 Detection of SARS-CoV-2 and Influenza with RT-qPCR

141 To detect SARS-CoV-2, an RT-qPCR targeting a region in the N2 gene was performed on the 142 QuantStudio[™] 7 Flex Real Time PCR system (Applied Biosystems, ThermoFisher). To amplify the N 143 gene region, a reaction mix was made using 5 µL TaqMan[™] Fast Virus 1-step Master Mix (Applied

Biosystems, Cat 4444434), 1.5 μL primer/probe mix from the 2019-nCoV CDC EUA kit (IDT, Cat
10006606) supplemented with 8.5 μL RNase free water to a total volume of 15 μL.

146 For Influenza qPCR a reaction mix was made using 5 µL TaqMan[™] Fast Virus 1-step Master Mix 147 (Applied Biosystems, Cat 4444434) 0.12 forward with μL primer (INFA-3) 148 5'TCTCATGGAATGGCTAAAGACAAG-3' (50µM) together with 0.2 µL probe (INFA-FP) FAM-5'-149 TTCACGCTCACCGTGC-3'-MGB (20µM) and 0.12 μL reverse primer (INFA-2) 5'-150 CAAAGCGTCTACGCTGCAGT-3' (50µM) supplemented with 9.56 µL RNase free water to a total 151 volume of 15 μ L.

- 152 Five μL of viral RNA was added to the reaction mixes. Thermal cycling conditions were 5 minutes at
- 153 50°C, 2 minutes at 95°C, followed by 45 cycles of 3 seconds at 95°C and 30 seconds at 60°C. Analysis
- 154 was done using the QuantStudio Real-Time PCR Software (Applied Biosystems, ThermoFisher).

155 Sanger sequencing for virus typing

- 156 Sanger sequencing was performed as described in Bloemen et al., 2022 with SARS-CoV-2 primers (S-
- 157 VOC-F/S-VOC-R). Additional primers for partial sequencing of influenzavirus
- 158 (AM_FW151/AM_RV397) were described by Schweiger et al., for adenovirus (F-hex1deg/R-hex2deg)
- by Allard et al. and for rotavirus (F-BEG9/R-END9) by Gouvea et al. [22]–[24].

160 Complete genomic sequencing of SARS-CoV-2

- 161 Complete genome sequencing of SARS-CoV-2 on RNA extracted from the Ag-RDT was done with the
- 162 nanopore technique using the ARTIC protocol as described in Wawina-Bokalanga et al. [25].
- 163 Sequences were analyzed with Nexclade v 2.0.0 (https://clades.nextstrain.org)

164

165 **RESULTS**

166 Sequencing of SARS-CoV-2 from archived Ag-RDT

167 A positive SARS-CoV-2 Ag-RDT (SARS-CoV-2 Rapid Antigen Test Nasal, Roche, Ref. 9901-NCOV-06G), 168 that had been used according to the test kit instructions to test an infected patient and was kept for 169 documentation purposes, had been stored at room temperature and not shaded from sunlight for 3 170 months. As a proof of concept, we tested whether residual viral genetic material could be extracted 171 from the test strip. On this strip, the positive test line was still clearly visible, and extraction was done 172 on the positive test strip zone of the test (zone d, indicated in Fig. 1). SARS-CoV-2 RNA could still be 173 detected by RT-q-PCR, with a Ct value of 27.6. Sanger sequencing on the extracted material allowed 174 to unambiguously determine the virus variant as Omicron BA.1, based on the partial sequence of the 175 S-gene RBD (Table 1).

We subsequently applied the same method to a Newgene SARS-CoV-2 Ag RDT that had been run with leftover material of a positive nasopharyngeal swab sample, and was stored under the same conditions, and were able to perform complete viral typing by WGS. Likewise, viral material could be retrieved and sequenced from archived SARS-CoV-2/influenza dual Ag-RDTs that had been run with positive nasopharyngeal swab samples (Table 1).

181 **Evaluation of specimen preparation**

182 The lateral flow rapid Ag tests used in this study all contain a test strip on which the sample is added 183 via the test window. The sample is absorbed onto the sample pad of the test strip, and is transported 184 via capillary flow to the distal end of the strip, flowing over the conjugate pad, test line and control 185 line. To investigate in which area of the test strip the largest amount of viral material from the 186 sample is maintained, and is thus best suited to be used to extract viral material, different zones of 187 the test strip were excised with scissors and used for nucleic acid extraction and RT-qPCR (Fig. 1). A 188 dual antigen test for influenza and COVID-19 (AMP Rapid Test CoV-2 Ag + Flu A+B) that had been run 189 with an influenza positive sample and a SARS-CoV-2 positive sample, was used for nucleic acid 190 extraction 3 months after the Ag test was run. The viral nucleic acid yield at different positions was 191 determined by RT-qPCR for influenza A and SARS-CoV-2 respectively (Table 1: CM-22-1177, CM-22-

192 6381). At all positions that were tested, viral genomic material could be harvested, with the sample 193 pad resulting in the highest yield for both SARS-CoV-2 and influenza, and the zone distal from the 194 test line giving the lowest yield for both viruses. We were able to successfully perform Sanger 195 sequencing on all extracts.

To evaluate the possibility of performing extraction from Ag-RDTs in a high throughput environment, we also tested the use of a punch biopsy sample taken at the test line of the strip. These punch biopsies can be picked without opening the test cassette. The use of a punch biopsy versus excision of the test line zone of the strip was compared using a Coris COVID-19 Ag test, and the resulting Ct value were approximately the same (Table 1: CM-22-8672). Since the biopsy procedure can be standardized and is relatively easy to use, we decided to use punch biopsies in further experiments.

202 To evaluate whether viral material is conserved at a comparable degree in different brands of SARS-203 CoV-2 Ag-RDTs, tests that were commonly used in Belgium at the time of this investigation were run 204 in parallel using the same positive sample (Ct of 18.5). This resulted in a clear positive test line on all 205 tests that were analyzed. Twenty-four hours after performing the Ag test, a punch biopsy was taken 206 from the test line zone and the sample pad of the test strip and used for extraction, followed by RT-207 qPCR, Sanger sequencing and WGS. All brands of SARS-CoV-2 Ag-RDTs that were tested allowed 208 detection of SARS-CoV-2 by RT-qPCR in the punch biopsy, and in all cases variant typing by Sanger 209 sequencing was possible (Table 1: CM-22-8702). This indicates that conservation of viral material in a 210 used Ag-RDT did not only occur in one specific brand, and that SARS-CoV-2 Ag-RDTs in general can be 211 used for genomic surveillance. We did however notice quite extensive differences in the RNA yield 212 that could be obtained, as indicated by the SARS-CoV-2 Ct value after extraction. Samples extracted 213 from Alltest, Newgene and Boson resulted in WGS data of good quality whereas the FlowFlex sample 214 was typable by WGS but data quality was poor.

Since the Ag-RDTs use buffers with different compositions, the effect of the buffer on RNA yield was
tested. Samples were loaded on an Ag test with and without addition of the test kit buffer (Table 1,

test performed on Roche nasal). For all samples tested, the Ct value of the extract was around 10 points higher when buffer was used, which equals approximately a 1000-fold lower concentration of viral genomic material. In general, the results of Sanger sequencing were successful when no buffer was used and good data quality was obtained by WGS. This indicates that some buffer components are deleterious for the viral genetic material, resulting in lower RNA concentrations and interfering with sequencing. WGS was not performed on samples that failed for Sanger sequencing given the high cost of nanopore sequencing.

224 Retrieval of viral material of influenzavirus, adenovirus and rotavirus from Ag-RDTs

An influenza A virus positive sample (nasopharyngeal swab in viral transport medium), that was tested in the routine diagnostic lab of the NRC, had been run on the influenza test strip of the AMP, Orient and Nadal SARS-CoV-2/influenzavirus dual antigen tests. A positive test line for influenza A was obtained with all three Ag tests. Three months after performing the Ag test, the test line zone was excised with scissors, and viral material was extracted. After extraction, sequences of influenza A could be retrieved by Sanger sequencing of part of the M gene for all three Ag tests.

231 Two fecal samples that were positive for both adenovirus and rotavirus by a routine diagnostic test in 232 the NRC lab were run on Coris GastroVir K-SeT rapid Ag tests. One sample displayed a positive test 233 line for both adeno- and rotavirus on the strip, while the other sample displayed a positive test line 234 for rotavirus but not for adenovirus. Punch biopsies were taken from the sampling pad, the rota test 235 line and the adeno test line of the strips. After extraction of these biopsies, PCR and Sanger 236 sequencing in the VP7 gene was performed for rotavirus detection. For both samples we detected 237 the presence of rotavirus G2 in extractions of the biopsies taken at all 3 sampling sites of the test 238 strip. The adenovirus PCR was also positive for both samples, and sequences of adenovirus 41 were 239 retrieved, again at all 3 sampling sites of the test strip, also in the sample that did not display a 240 positive test band.

242

243

244 **DISCUSSION**

Whereas RT-qPCR continues to be the gold standard for COVID-19 diagnosis, rapid Ag-RDTs are widely used since they offer the benefit of a very short time to results, are cheaper, and easy to use. A disadvantage of testing through Ag-RDTs so far was that no leftover sample material was available for genomic characterization of positive samples. Our finding that the test strip used in rapid Ag tests are suited to preserve intact viral genomic material, even for months, and can serve as source material for genomic characterization of the virus, could be a gamechanger in the COVID-19 testing strategy.

We demonstrated that a SARS-CoV-2 Ag-RDT that was stored at room temperature up to 3 months could still serve as source material for genomic surveillance. This implies that used Ag test can be easily sent to sequencing facilities, even by regular mail. This provides an easy and cheap way to establish baseline genomic surveillance in countries/regions with limited resources, which would otherwise remain blind spots thus allowing for novel virus variants to remain under the radar. This could therefore mean an important improvement in the global coverage of genomic surveillance.

258 In this study, we have tested a total of 9 different Ag-RDTs for SARS-CoV-2 detection (with or without 259 concurrent influenza detection), and were able to successfully perform Sanger sequencing on 260 extracted material from all of these. The difference between the original Ct in the sample and the Ct 261 value after extraction of the test strip largely differed depending on the Ag-RDT used. Our results 262 indicated that the buffer used by some Ag tests contains a chemical compound that breaks down the 263 viral RNA and has a negative effect on the quality of sequencing data. For instance, in case of the 264 Roche nasal test, use of the test kit buffer resulted in a much lower viral RNA yield and made the 265 extract unuasable for sequencing. Use of the same Ag test when putting the samples directly on the

cassette (without buffer) resulted in much better yields and good sequencing results, both by Sangerand by WGS.

268 Nazario-Toole et al. demonstrated recently that whole genome sequencing of SARS-CoV-2 from excess clinical specimens processed using the BinaxNOWTM COVID-19 Ag Card was feasible [26]. They 269 270 however did not assess the effect of prolonged room temperature storage of completed Ag cards, 271 nor did they study different brands of SARS-CoV-2 Ag-RDTs, or Ag-RDTs for other viruses. 272 We have shown that this method is more widely useable, by demonstrating that genomic material of 273 influenza virus, adenovirus and rotavirus can also be retrieved from rapid Ag tests. Especially during 274 the upcoming winter seasons, when an upsurge in COVID-19 is to be expected with concomitant 275 circulation of other respiratory pathogens such as influenza virus, the use of Ag-RDTs that allow 276 combined detection of multiple respiratory pathogens, such as COVID-Flu a/b combo tests, can prove 277 to be a very cost-efficient testing strategy. We have now shown that the use of these Ag tests can be 278 combined with genomic surveillance, which will remain equally important in the monitoring of novel

279 variants.

We were able to confirm the usability for 10 commercial Ag-RDTs which are commonly used in Belgium. Since it was not possible to test all commercial Ag-RDTs, a validation experiment for each brand and with use of different buffer compositions should be performed prior to large scale implementation of a certain Ag-RDT in genomic surveillance. We plan to further optimize the method for high-throughput processing.

285

286 **ACKNOWLEDGEMENTS**

287 UZ Leuven, as national reference centre, is supported by Sciensano, which is gratefully
288 acknowledged.

290 **REFERENCES**

- [1] WHO, "WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard
 With Vaccination Data." [Online]. Available: https://covid19.who.int/. [Accessed: 16-May2022].
 [2] J. R. Marcelin, A. Pettifor, H. Janes, E. R. Brown, J. G. Kublin, and K. E. Stephenson, "COVID-19
- Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective,"
 Open Forum Infect. Dis., 2022.
- 297 [3] V. Pilkington, S. M. Keestra, and A. Hill, "Global COVID-19 Vaccine Inequity: Failures in the
- 298First Year of Distribution and Potential Solutions for the Future," Front. Public Heal., vol. 10,
- 299 no. March, pp. 1–8, 2022.
- 300 [4] V. M. Corman et al., "Comparison of seven commercial SARS-CoV-2 rapid point-of-care
- antigen tests: a single-centre laboratory evaluation study," *The Lancet Microbe*, vol. 2, no. 7,
 pp. e311–e319, 2021.
- N. Kohmer *et al.*, "Article the comparative clinical performance of four SARS-CoV-2 rapid
 antigen tests and their correlation to infectivity in vitro," *J. Clin. Med.*, vol. 10, no. 2, pp. 1–11,
 2021.
- WHO, "Antigen-detection in the diagnosis of SARS-CoV-2 infection," *Interim Guid.*, no. 6
 October, 2021.
- WHO, "Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing,"
 Interim Guid., no. 9 March, pp. 1–16, 2022.
- 310 [8] WHO, "Tracking SARS-CoV-2 variants." [Online]. Available:
- 311 https://www.who.int/activities/tracking-SARS-CoV-2-variants. [Accessed: 16-May-2022].
- 312 [9] ECDC, "SARS-CoV-2 variants of concern as of 12 May 2022." [Online]. Available:

- 313 https://www.ecdc.europa.eu/en/covid-19/variants-concern. [Accessed: 16-May-2022].
- 314 [10] J. D. Robishaw et al., "Genomic surveillance to combat COVID-19: challenges and
- 315 opportunities," *The Lancet Microbe*, vol. 2, no. 9, pp. e481–e484, 2021.
- 316 [11] WHO, "Recommendations For National SARS-Cov-2 Testing Strategies And Diagnostic
- 317 Capacities," Interim Guid., no. June 25, pp. 1–16, 2021.
- 318 [12] WHO, Genomic sequencing of SARS-CoV-2, no. January 8. 2021.
- 319 [13] A. Rambaut et al., "A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
- 320 genomic epidemiology," *Nat. Microbiol.*, vol. 5, no. 11, pp. 1403–1407, 2020.
- 321 [14] M. Bloemen et al., "Fast detection of SARS-CoV-2 variants including Omicron using one-step

322 RT-PCR and Sanger sequencing," J. Virol. Methods, vol. 304, no. March, p. 114512, 2022.

- 323 [15] E. Wollants, P. Maes, I. Thoelen, F. Vanneste, M. Rahman, and M. Van Ranst, "Evaluation of a
- norovirus sampling method using sodium dodecyl sulfate/EDTA-pretreated chromatography
 paper strips," J. Virol. Methods, vol. 122, no. 1, pp. 45–48, 2004.
- 326 [16] P. Maes et al., "Poliovirus sampling by using sodium dodecyl sulfate/EDTA-pretreated
- 327 chromatography paper strips," *Biochem. Biophys. Res. Commun.*, vol. 325, no. 3, pp. 711–715,
 328 2004.
- M. Rahman *et al.*, "Chromatography Paper Strip Method for Collection, Transportation, and
 Storage of Rotavirus RNA in Stool Samples," *J. Clin. Microbiol.*, vol. 42, no. 4, pp. 1605–1608,
 2004.
- K. T. Zlateva, P. Maes, M. Rahman, and M. Van Ranst, "Chromatography paper strip sampling
 of enteric adenoviruses type 40 and 41 positive stool specimens," *Virol. J.*, vol. 2, pp. 1–5,
 2005.

335 [19] ECDC, "Increase in severe acute hepatitis cases of unknown aetiology in children," Rapid Risk

- 336 *Assess.*, no. April 28, pp. 1–19, 2022.
- J. M. Baker *et al.*, "Acute Hepatitis and Adenovirus Infection Among Children Alabama,
 October 2021-February 2022.," *MMWR. Morb. Mortal. Wkly. Rep.*, vol. 71, no. 18, pp. 638–
- 339640, 2022.
- 340 [21] K. Marsh et al., "Investigation into cases of hepatitis of unknown aetiology among young
- 341 children, Scotland, 1 January 2022 to 12 April 2022," *Eurosurveillance*, vol. 27, no. 15, pp. 1–7,
 342 2022.
- 343 [22] B. Schweiger, I. Zadow, R. Heckler, H. Timm, and G. Pauli, "Application of a fluorogenic PCR
- 344 assay for typing and subtyping of influenza viruses in respiratory samples," J. Clin. Microbiol.,
- 345 vol. 38, no. 4, pp. 1552–1558, 2000.
- A. Allard, B. Albinsson, and G. Wadell, "Rapid typing of human adenoviruses by a general PCR
 combined with restriction endonuclease analysis," *J. Clin. Microbiol.*, vol. 39, no. 2, pp. 498–
 505, 2001.
- V. Gouvea *et al.*, "Polymerase chain reaction amplification and typing of rotavirus nucleic acid
 from stool specimens," *J. Clin. Microbiol.*, vol. 28, no. 2, pp. 276–282, 1990.
- T. Wawina-Bokalanga *et al.*, "Genetic diversity and evolution of SARS-CoV-2 in Belgium during
 the first wave outbreak," *bioRxiv*, p. 2021.06.29.450330, 2021.
- 353 [26] A. Nazario-Toole, H. M. Nguyen, H. Xia, D. N. Frankel, J. W. Kieffer, and T. F. Gibbons,
- 354 "Sequencing SARS-CoV-2 from antigen tests," *PLoS One*, vol. 17, no. 2 February, pp. 1–8, 2022.
- 355
- 356
- 357
- 358

359 **TABLE**

		SAMPLE			ANTIGEN TEST				RESULT		
_		virus	code	sample Ct	Name	use of buffer	region*	∆t**	extract Ct	Sanger seq	WGS
		SARS-CoV-2	CV-22-2069	UNK	Roche nasal	YES	zone d	3 mths	27.6	BA.1	ND
		SARS-CoV-2	X-22-0205	UNK	Newgene	YES	zone d	3 mths	ND	BA.2	BA.2
	RDT	SARS-CoV-2	CM-22-5857	18.6	AMP	YES	zone d	3 mths	26.7	BA.2	ND
	Ag-	SARS-CoV-2	CM-22-5857	18.6	Orient	YES	zone d	3 mths	25.6	BA.2	ND
	ived	SARS-CoV-2	CM-22-5857	18.6	Nada	YES	zone d	3 mths	26.3	BA.2	ND
	arch	Influenza A	BE-22-2238	24.6	AMP	YES	zone d	3 mths	35.4	H3N2	ND
		Influenza A	BE-22-2238	24.6	Orient	YES	zone d	3 mths	32.2	H3N2	ND
		Influenza A	BE-22-2238	24.6	Nada	YES	zone d	3 mths	32.2	H3N2	ND
		SARS-CoV-2	CM-22-1177	16.5	AMP	YES	zone a	3 mths	17.3	BA.2	ND
		SARS-CoV-2	CM-22-1177	16.5	AMP	YES	zone b	3 mths	22.2	BA.2	ND
		SARS-CoV-2	CM-22-1177	16.5	AMP	YES	zone c	3 mths	19.6	BA.2	ND
		SARS-CoV-2	CM-22-1177	16.5	AMP	YES	zone d	3 mths	21.7	BA.2	ND
		SARS-CoV-2	CM-22-1177	16.5	AMP	YES	zone e	3 mths	22.6	BA.2	ND
		Influenza A	CM-22-6381	18.5	AMP	YES	zone a	3 mths	28.6	H3N2	NA
		Influenza A	CM-22-6381	18.5	AMP	YES	zone b	3 mths	29.9	H3N2	NA
	u	Influenza A	CM-22-6381	18.5	AMP	YES	zone c	3 mths	29.3	H3N2	NA
		Influenza A	CM-22-6381	18.5	AMP	YES	zone d	3 mths	30.6	H3N2	NA
	ratic	Influenza A	CM-22-6381	18.5	AMP	YES	zone e	3 mths	33.3	H3N2	NA
	repa	SARS-CoV-2	CM-22-8672	16.5	Coris COVID-19	YES	zone d	24h	28.7	ND	ND
	id ua	SARS-CoV-2	CM-22-8672	16.5	Coris COVID-19	YES	PB zone d	24h	28.8	ND	ND
	ame	SARS-CoV-2	CM-22-8702	18.5	Alltest	YES	PB zone a+d	24h	27	BA.2	BA.2
	spe	SARS-CoV-2	CM-22-8702	18.5	Newgene	YES	PB zone a+d	24h	21.3	BA.2	BA.2
	n of	SARS-CoV-2	CM-22-8702	18.5	FlowFlex	YES	PB zone a+d	24h	20.9	BA.2	BA.2
	latic	SARS-CoV-2	CM-22-8702	18.5	Boson	YES	PB zone a+d	24h	26.5	BA.2	BA.2
	Evalt	SARS-CoV-2	CM-22-6505	12.6	Roche nasa	YES	PB zone a+d	72h	32.5	Failed	ND
Other virtuese	-	SARS-CoV-2	CM-22-6505	12.6	Roche nasa	NO	PB zone a+d	72h	19.5	BA.2	BA.2
		SARS-CoV-2	CM-22-6516	20.6	Roche nasa	YES	PB zone a+d	72h	35.8	Failed	ND
		SARS-CoV-2	CM-22-6516	20.6	Roche nasa	NO	PB zone a+d	72h	28.8	BA.2	BA.2
		SARS-CoV-2	CM-22-3708	18.1	Roche nasa	YES	PB zone a+d	72h	32.9	Failed	ND
		SARS-CoV-2	CM-22-3708	18.1	Roche nasa	NO	PB zone a+d	72h	23.4	BA.4/BA.5	BA.5.1
		SARS-CoV-2	CM-22-4853	14.7	Roche nasa	YES	PB zone a+d	72h	33.3	Failed	ND
		SARS-CoV-2	CM-22-4853	14.7	Roche nasa	NO	PB zone a+d	72h	22.0	BA.4/BA.5	BA.4
		SARS-CoV-2	CM-22-7973	15.8	Roche nasa	YES	PB zone a+d	72h	31.2	Failed	ND
		SARS-CoV-2	CM-22-7973	15.8	Roche nasa	NO	PB zone a+d	72h	22.9	BA.4/BA.5	BA.5.1
	Ises	AdV 40/41	F14284	UNK	Coris Gastro	YES	РВ	24u	pos	AdV 41	NA
	·virt	AdV 40/41	F14298	UNK	Coris Gastro	YES	РВ	24u	pos	AdV 41	NA
	ther	Rotavirus	F14284	UNK	Coris Gastro	YES	РВ	24u	pos	G2	NA
	0	Rotavirus	F14298	UNK	Coris Gastro	YES	PB	24u	pos	G2	NA

360 Table 1: Retrieval of viral material from rapid Ag tests

361

- 362 * region of test strip excised and used for extraction, as indicated in Figure 1
- 363 ** time between adding sample to Ag-RDT and nucleic acid extraction from the test strip
- 364 PB= punch biopsy; UNK = unknown; ND = Not Done; NA = not available
- 365 WGS results of poor quality (as indicated by Nextclade) are shaded in grey.

367 **FIGURE**



Figure 1: Opened cassette of an Orient Gene Influenza & COVID-19 Ag Combo Rapid Test, with dashed lines indicating the position of the sample windows (S) and result windows (R), displaying a positive test line (T) and control line (C). Regions excised for nucleic acid extraction (a-e) are delineated with dotted lines.